Please login to the form below

Not currently logged in
Email:
Password:

Banned Chinese medicine in the UK

More than 900 packs of a potentially dangerous traditional Chinese medicine are on the UK market despite warnings issued by the MHRA

More than 900 packs of a potentially dangerous traditional Chinese medicine (TCM) are currently on the UK market despite warnings issued by the Medicines and Healthcare products Regulatory Agency (MHRA).

The unlicensed herbal product - Jingzhi Kesou Tan Chuan Wan - was distributed to 20 TCM and herbal medicine outlets throughout the UK. A recall was initiated by the distributor, Ekong International, in February 2010, however, more than three quarters of the stock brought in from China has still not been returned.

It has been revealed that new labelling in English had been applied to packs to conceal the original label, which contained the Chinese symbols for Aristolochia, a banned toxic and carcinogenic plant derivative.

Exposure to aristolochic acids can result in kidney failure and the development of cancer, particularly of the urinary tract.

The MHRA has written to TCM trade and practitioner associations to ensure that none of their members are supplying the product.

29th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics